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Objective: The aim of this study was to assess asthma control using salmeterol plus
fluticasone propionate (FP) in combination (SFC) versus salmeterol or FP as
monotherapy in patients with mild to moderate asthma.
Methods: In this randomised, double-blind, parallel-group study, 322 symptomatic
patients were recruited, of which 282 were randomised to receive either salmeterol
(50 mg), FP (250 mg), or SFC (50 mg/250 mg), via a single DiskusTM inhaler twice daily
for 12 months. Outcome variables included the number of patients requiring an
increase in study medication and the number experiencingX2 exacerbations during
the 12-month treatment period. Airway hyper-responsiveness (AHR) and lung
function tests were performed at clinic visits. Peak expiratory flow, rescue
medication use, symptom scores and adverse events were recorded in diary cards.Elsevier Ltd. All rights reserved.
as sponsored by GlaxoSmithKline plc.
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Control of mild to moderate asthma over 1-year 3Results: Fewer patients required an increase in study medication with SFC (10.5%)
than with either FP (34.8%) or salmeterol (61.1%) (Po0.001). Significantly fewer
patients experienced X2 exacerbations with SFC (4.2%), compared with FP (17.4%;
Po0.01) or salmeterol (40%; Po0.001). SFC improved AHR to a significantly greater
extent than FP (methacholine PC20 ¼ 1.8mg/ml vs. 1.1mg/ml; Po0.05) or
salmeterol (methacholine PC20 ¼ 1.8mg/ml vs. 0.7mg/ml; Po0.001).
Conclusions: The protection against exacerbations may be attributed to better
control of inflammation, AHR and lung function parameters achieved with salmeterol
and FP in combination, compared with either treatment alone.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease characterised by
inflammation, which contributes to airway hyper-
responsiveness (AHR), airflow limitation and symp-
toms.1 Even in the absence of symptoms, inflam-
mation and AHR still exist,2 and are usually present
in patients defined as having mild asthma.3
Asthma management guidelines, such as those
produced by the Global Initiative for Asthma
(GINA),1 recommend pharmacological intervention
based on disease severity. Inhaled corticosteroids
(ICS) are advocated as the most effective controller
medication, and their use is recommended in all
patients with persistent asthma, including mild
persistent asthma. These anti-inflammatory agents
are known to reduce inflammation, AHR and
exacerbations.4 They should be started early in
the disease course in order to slow down or prevent
structural changes from occurring as a result of
inflammation.5,6 Death due to asthma is usually
characterised by extensive infiltration of inflam-
matory cells.1,7 Inflammation may also be present
in patients with mild disease; consequently, these
patients are at risk of asthma-related death.8–10
Long-acting beta-agonists (LABAs) are advocated for
use in combination with ICS for moderate to severe
persistent asthma.1 They have proven bronchodilator
properties, and have beneficial effects on smooth
muscle and epithelial cell proliferation, symptom
reduction, and lung function.11–13 Epithelial dysfunc-
tion in asthma may lead to beta receptor impairment;
this in turn contributes to AHR.14 Therefore, an agent
with beneficial effects on epithelial cell proliferation
may help to protect against AHR.
Several studies have demonstrated that patients
with moderate to severe persistent asthma can
achieve better control with ICS, either by adjusting
the dose, or by using ICS and LABAs in combina-
tion.15–21 Very few studies have examined the
effects of combination therapy in mild asthma.
Given its proven clinical efficacy in moderate to
severe asthma, combination therapy may be of
benefit in patients with milder disease.Against this background, the aim of the current
study was to assess long-term control achieved in
clinically representative patients with mild to
moderate asthma using salmeterol plus fluticasone
propionate (FP) in combination (SFC) versus salme-
terol or FP as monotherapy.Methods
This was a 12-month, randomised, double-blind,
parallel-group study, with a 2-month run-in period.
Patients were recruited between December 1997
and January 2000, and completed the double-blind
treatment period in December 2000. There was a
2-year open-label follow-up period (the results of
open-label phase are not reported here). The aim
of the study was to establish treatment effective-
ness of salmeterol, FP and SFC in patients with mild
to moderate asthma. The study was performed in
accordance with the Declaration of Helsinki, and all
patients provided written informed consent to
participate. The ethical committee at the Univer-
sity Hospital of Northern Sweden approved the
study.Patients
Patients were recruited from approximately 4000
individuals with asthma who had participated in
large epidemiological studies of the general popu-
lation in Northern Sweden.22–25 Men and women
aged 18–70 years with clinically representative
mild to moderate persistent asthma, with symp-
toms at least twice a week, were eligible for
inclusion.
Patients were required to have at least one of the
following: AHR, demonstrated by methacholine
challenge with PC20o8mg/ml (the concentration
required to provoke a 20% reduction in forced
expiratory volume in one second [FEV1]);diurnal
variability in peak expiratory flow (PEF) ofX20% on
43 days during the last 14 days of the run-in; a
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lowest PEF reading during any 7 days in the run-in
period; or a reversible increase of X15% in FEV1 or
PEF after salbutamol inhalation (0.8mg). Patients
were excluded if they were taking daily doses of ICS
X1200 mg; had experienced one or more life-
threatening exacerbation requiring hospitalisation
during the previous 12 months; were hypersensitive
to beta-agonists or ICS; were pregnant or lactating;
or had a respiratory tract infection during the 4
weeks prior to run-in.Study design
Following a 1-month pre-run-in period on previous
therapy, and a 1-month run-in period, during which
the dose of ICS was reduced (in subjects using ICS)Screened asthm
322 patients rec
282 patients rand
SFC (50 µg/250 µg)
(n=95)
FP (250
(n=92
12-month blinded phase
86 patients completed
9 patients withdrew:
•     2 adverse events
•     1 failure to return
•     1 treatment failure
•     1 personal reasons
•     3 pregnancies
•     1 non-compliance
12-month blinded ph
87 patients complete
5 patients withdrew:
•     2 adverse events
•     2 non-complianc
•     1 remission of as
follow-up* follow-u
Figure 1 Study design and patient randomisation. FP: flutica
*Not reported here.to a maximum of budesonide 400 mg per day or
equivalent, patients were randomised to receive
salmeterol (50 mg), FP (250 mg), or SFC (50 mg/
250 mg) via a DiskusTM inhaler twice daily for 12
months (Fig. 1). Both the patient and the investi-
gator administering the medications were blinded
to the study treatments. Blinded medication packs
were assigned to patients at randomisation; the
investigator was supplied with individual sealed
envelopes for breaking each patient’s code. All
individuals directly associated with the conduct of
the study were blinded until either the end of 12
months or in the case of a second exacerbation of
asthma, which demanded a change in medication.
Patient compliance with medication was assessed
by the investigator at each clinic visit by comparing
the number of doses taken using the DiskusTM dose
counter, with the number of days since the lastatics 
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•    1 didn’t want to continue
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sone propionate; SFC: salmeterol plus FP in combination.
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Control of mild to moderate asthma over 1-year 5clinic visit. Each patient was required to maintain a
compliance level of at least 70%.
Salbutamol dry powder (0.2mg) or salbutamol
aerosol (0.1mg) was used as rescue medication.
Treatment effectiveness (assessed via the need
for dosage increase, the number of exacerba-
tions, AHR, lung function, symptoms and/or rescue
medication use) and safety assessments (adverse
events) were assessed during clinic visits and/or
via patient diary cards (which were used for
7 days prior to randomisation and for 14 days
prior to each post-randomisation clinic visit). Clinic
visits occurred at 1, 3, 6, 9 and 12 months after
randomisation.Treatment effectiveness
The primary variable was the number of patients
requiring an increase in study medication. An
increase in study medication was necessary if
patients’ asthma was not controlled. Patients’
asthma was defined as not controlled if they had
experienced X2 asthma exacerbations during the
12-month study period, or if they had any two of
the following during the 2 weeks prior to the 12-
month clinic visit: night symptoms requiring rescue
medication more than twice; daily symptoms
requiring rescue medication more than every other
day; diurnal variability of mean morning PEF X20%
on 44 days; a reduction in PEF of X15%; or a
decrease in clinic FEV1X10%. Patients randomised
to salmeterol (50 mg) were transferred to SFC
(50 mg/250 mg), patients randomised to FP (250 mg)
had their dose increased to FP (500 mg), and those
patients randomised to SFC (50 mg/250 mg) were
given SFC (50 mg/500 mg). Patients who needed an
increase in study medication as a result of a second
exacerbation during the 12-month treatment per-
iod stopped the blinded phase of the study and
continued in the study on an open-label basis.
Secondary variables included: the number of
patients experiencing X2 exacerbations during
the 12-month treatment period, clinic lung func-
tion tests, AHR and diary card data. Exacerbations
were defined as any deterioration in asthma that
required an increase in rescue medication use
(beta-agonist) over that used during the run-in
period of46 puffs/day forX2 consecutive days, or
an increase of X2 doses/day in regular inhaled
medication (study medication or additional ICS) for
X2 days by the patient’s own decision, or X2 days
when asthma symptoms prevented the patient’s
work or normal activities. If rescue medication was
insufficient, exacerbations were treated with oral
prednisolone (25mg) for 5 days.Lung function (FEV1 and forced vital capacity
[FVC]) were determined at clinic visits. Methacho-
line tests were performed at baseline and after 12
months to assess AHR; patients were required to be
free from study medication and LABAs for at least
24 h and from short-acting beta-agonists for at least
8 h prior to the test. Patient diary cards were used
to record morning and evening PEF, rescue medica-
tion use, and daytime and nighttime asthma
symptom scores.
Safety assessments
Adverse events were recorded by the patient in
their diary cards and confirmed at clinic visits. In
addition, adverse events were recorded by the
investigating physician at clinic visits.
Statistical methods
A sample size of 300 patients was calculated on the
basis of 80% power to detect a difference of 20%
between any pair of treatment groups (i.e. SFC vs.
FP/salmeterol) in the percentage of patients
requiring an increase in dose in any one year.
Statistical analyses were performed on data
derived from the intent-to-treat population, which
consisted of all patients who were randomised to
treatment and received at least one dose of study
medication. The statistical techniques used were
the pairwise chi-square test to compare proportions,
the analysis of covariance adjusted for age, sex and
stratum, and the Van Elteren extension to the
Wilcoxon Rank Sum test,26 stratified by stratum,
for lung function measurements. Two-sided prob-
ability levelsp5% were considered to be significant.
Any data recorded after unblinding were not
included in the analysis. Thus, for the assessments
recorded at each clinic visit and those derived over
the last two weeks before each clinic visit, a last
observation carried forward approach was used to
account for any missing data.
Results
Patient characteristics
A total of 322 individuals entered the run-in period,
of which 282 were randomised to treatment. The
baseline characteristics of the patients in the three
treatment groups were similar (Table 1). Patients
had mild to moderate asthma (mean FEV1 was
490% predicted; 48% reported p1 symptom per
day; 49% reported p1 nighttime or early morning
waking per 2 weeks). A total of 192 patients (68%)
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Table 1 Baseline characteristics of 282 patients with mild to moderate asthma randomised to 12 months’
treatment with fluticasone propionate (FP), salmeterol or salmeterol plus FP in combination (SFC).
SFC (n ¼ 95) FP (n ¼ 92) Salmeterol (n ¼ 95)
Age (years) 39.9 (11.9) 39.1 (12.0) 40.7 (12.3)
Male:female (%) 34:66 42:58 37:63
Proportion with asthma
410 years (%) 58 58 71
Smokers (%) 14 12 17
Weight (kg) 72.9 (14.8) 75.3 (13.2) 76.7 (17.0)
Height (cm) 168.8 (9.6) 169.7(10.1) 169.6 (8.9)
FEV1% predicted (%) 92.1 93 94.9
Methacholine PC20 (mg/ml) 0.5 (533)
 0.6 (331) 0.9 (337)
Methacholine PC20o8mg/ml (%) 97.8 97.8 98.9
Positive reversibility test (%)y 22.1 17.4 21.1
PEF- variability (%)y 16.8 17.4 24.2
Previous medication (%)z
SABA 93 95 95
LABA 20 22 28
CS 73 62 66
Othery 5 3 3
Mean (SD) values presented unless otherwise stated.
Mean value (coefficient of variation at baseline).
yMedications (not mutually exclusive) used prior to randomization.
zAs defined in Methods.
ySodium cromoglycate, montelukast sodium, or corticosteroids and bronchodilators combined. CS: corticosteroids; FEV1:
forced expiratory flow in one second; LABA: long-acting beta-agonist; SABA: short-acting beta-agonist.
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B. Lundba¨ck et al.6had previously received ICS (the median dosage was
budesonide 500 mg per day or equivalent). Of all
tested patients, 98% were hyperreactive to metha-
choline at randomisation, 19% demonstrated a
variability in PEF and 20% had a positive reversi-
bility test according to the definitions described in
the Methods section.
In total, 93.3% of patients completed the 12-
month treatment period (SFC: 90.5%; FP: 94.6%;
salmeterol: 94.7%). Reasons for withdrawal in-
cluded adverse events, non-compliance with study
medication, and failure to return to the clinic
(Fig. 1). Compliance with medication was470% for
all patients throughout the study period.p<0.001
Figure 2 Patients with mild to moderate asthma requir-
ing an increase in study medication during 12 months’
treatment with fluticasone propionate (FP), salmeterol
or salmeterol plus FP in combination (SFC) (n ¼ 282).
yPairwise Chi-square test.Treatment effectiveness
Fewer patients required an increase in study
medication with SFC (n ¼ 10; 10.5%) than with
either FP (n ¼ 32; 34.8%) or salmeterol (n ¼ 58;
61.1%). This difference was statistically significant
(Po0.001; Fig. 2). The main reason for dosage
adjustment was X2 exacerbations.
The percentage of patients experiencing X2
exacerbations during the 12-month treatment period
was significantly lower in the SFC group than in the FPgroup (4.2% vs. 17.4%; Po0.01), and the salmeterol
group (4.2% vs. 40.0%; Po0.001) (Fig. 3). Improve-
ment in AHR after 12 months was significantly greater
for patients in the SFC group compared with patients
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Figure 3 Proportion of patientsy with mild to moderate
asthma who experienced X2 exacerbations during 12
months’ treatment with fluticasone propionate (FP),
salmeterol or salmeterol plus FP in combination (SFC)
(n ¼ 282). yPairwise Chi-square test.
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Figure 4 Improvement in meany methacholine PC20 in
282 patients with mild to moderate asthma after 12
months’ treatment with fluticasone propionate (FP),
salmeterol or salmeterol plus FP in combination (SFC).
yGeometric mean adjusted for baseline value, stratum,
age and sex.
Table 2 Lung function data for 282 patients with mild to
with fluticasone propionate (FP), salmeterol or salmete
baseline presented.y
SFC
(n ¼ 95)
FP
(n ¼ 92)
Salmete
(n ¼ 95
Morning PEF (l/min) 38 21 7
PEF diurnal variation 2.5 1.6 0.2
FEV1 (l) 0.09 0.02 0.05
FVC (l) 0.07 0.05 0.02
yMean adjusted for baseline value, stratum, age and sex.
FEV1: forced expiratory volume in one second; FVC: forced vital
*po0.05, **po0.01, ***po0.001.
NS ¼ not significant.
Control of mild to moderate asthma over 1-year 7in the FP (methacholine PC20 ¼ 1.8 vs. 1.1mg/ml;
Po0.05) or salmeterol (methacholine PC20 ¼ 1.8 vs.
0.7mg/ml; Po0.001) groups (Fig. 4).
Lung function, measured as mean change from
baseline in morning PEF, was significantly improved
with SFC compared with FP (38 vs. 21 l/min;
Po0.01) and salmeterol (38 vs. 7 l/min; Po0.001)
(Table 2). FEV1 and FVC were also significantly
increased from baseline with SFC compared with
salmeterol (Table 2).
The median proportion of symptom-free days was
higher in the SFC (66.7%) and FP (67.9%) groups
than in the salmeterol group (44.5%; Po0.05). The
corresponding figures for median symptom-free
nights were also higher in the SFC group (100%)
and FP group (100%) compared with the salmeterol
group (92.3%; Po0.001). In addition, the median
proportion of rescue medication-free days was
significantly higher in the SFC (85.7%) and FP
(85.7%) groups than in the salmeterol group (60%;
Po0.05). The median proportion of patients with
rescue medication-free nights was 100% for all
three-treatment groups.
Safety assessments
The total number of patients who reported any
adverse event during the study were 92 (97%) in the
SFC group, 88 (96%) in the FP group and 90 (95%) in
the salmeterol group. The most frequently re-
ported adverse events are summarised in Table 3.
The most common adverse event was respiratory
tract infections (74% in the SFC group, 78% in the FP
group, and 55% in the salmeterol group).Discussion
The aim of this study was to determine treatment
effectiveness, assessed via the need for dosagemoderate asthma randomised to 12 months’ treatment
rol plus FP in combination (SFC). Mean change from
rol
)
Difference
SFCFP
Difference
SFCsalmeterol
Difference
FPsalmeterol
+16.9** +30.7*** +13.9*
0.9NS 2.3*** 1.4*
+0.07NS +0.14*** +0.07NS
+0.01NS +0.09* +0.08NS
capacity; PEF: peak expiratory flow.
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Table 3 Summary of the most frequently occurring (X5%) adverse events in 282 patients with mild to moderate
asthma randomised to 12 months’ treatment with fluticasone propionate (FP), salmeterol or salmeterol plus FP in
combination (SFC).
SFC (n ¼ 95) n (%) FP (n ¼ 92) n (%) Salmeterol (n ¼ 95) n (%)
RTI 70 (74) 72 (78) 52 (55)
Musculoskeletal pain 9 (9) 11 (12) 8 (8)
Gastroenteritis 11 (12) 5 (5) 5 (5)
Hoarseness/dysphonia 10 (11) 8 (9) 2 (2)
Sinusitis 8 (8) 5 (5) 4 (4)
Headaches 2 (2) 6 (7) 8 (8)
Tonsillitis 4 (4) 4 (4) 5 (5)
Bronchitis 5 (5) 3 (3) 4 (4)
Cough 2 (2) 3 (3) 7 (7)
Chest symptoms 1 (1) 5 (5) 4 (4)
Muscle cramps and spasms 6 (6) 0 (0) 2 (2)
Hypertension 0 (0) 5 (5) 2 (2)
Candidiasis 6 (6) 0 (0) 1 (1)
RTI: upper respiratory tract infections plus viral respiratory infections.
B. Lundba¨ck et al.8increase, reduction in exacerbations, diminished
AHR and normalisation of lung function in patients
with mild to moderate asthma randomised to
receive salmeterol, FP, or SFC for a 12-month
period. The results showed that significantly fewer
patients in the SFC group required an increase in
study medication to achieve effective control
compared with the FP or salmeterol groups. In
addition, significantly fewer exacerbations were
observed in the SFC group compared with the FP
and salmeterol groups. Improvement in AHR was
significantly greater in the SFC group compared
with the FP and salmeterol groups. Lung function
tests (PEF, FEV1 and FVC) were significantly
improved with SFC relative to salmeterol.
These findings demonstrate that the combination
of an anti-inflammatory agent (FP) with a LABA
(salmeterol) is more effective in the long-term
control of mild to moderate asthma than FP or
salmeterol monotherapy. Asthma, even during
symptom-free periods, is characterised by inflam-
mation which contributes to AHR. It may be
expected that monotherapy with FP should provide
adequate control in mild asthma. The beneficial
effects on AHR with SFC compared with FP were
somewhat surprising in this respect. The results
observed with salmeterol were not unexpected;
use of salmeterol alone is not recommended even
in mild asthma. These results demonstrate the
benefits of regular anti-inflammatory treatment for
persistent asthma, particularly with the SFC com-
bination.
There are several possible explanations for the
superior efficacy of SFC over FP observed in this
study. In addition to their recognised properties,LABAs may modulate neurotransmission and inhibit
mast cell mediator release, thereby potentiating
the anti-inflammatory actions of ICS.27 Further-
more, ICS are thought to protect against the loss of
beta2 receptors, and may therefore enhance the
long-term benefits of beta-agonists.15,27,28 ICS plus
LABAs have demonstrated greater clinical efficacy
than other combinations, or higher doses of ICS
monotherapy.29 Given that patients with mild
asthma present with airway inflammation, oedema,
plasma exudation, smooth muscle hypertrophy and
denudation of epithelium,30–33 this supports the
role of ICS plus LABAs in mild asthma. The results of
the gaining optimal asthma control (GOAL) study
indicated the beneficial effects of ICS plus LABA
also in mild to moderate asthma.34
Evidence suggests that, in the short-term, AHR is
associated with inflammation, while, in the long-
term, it is linked to impaired lung function.34 AHR is
an exaggerated bronchoconstrictor response, which
indicates that beta receptors may be associated
with its progression via an effect on cholinergic
nerve transmission in smooth muscle (not via an
effect on inflammation).27 Given such emerging
evidence, it is not surprising that combination
therapy, which can address both inflammatory and
non-inflammatory components of asthma (even in
early disease stages), is being investigated.35,36
The patients included in this study were taken
from a population of approximately 4000 asthmatic
subjects derived from epidemiologic studies22,23
and represent patients seen in a real-life situation.
The overall prevalence of asthma in the general
population of the area was close to 10%.25 The
patients included in this study were symptomatic
ARTICLE IN PRESS
Control of mild to moderate asthma over 1-year 9on their previous therapy (two-thirds were taking
ICS). The duration of asthma wasX10 years in over
50% of patients. It is widely acknowledged that
once diagnosed, patients can remain classified and
treated based on their initial diagnosis for many
years, hence the persistence of symptoms and the
relatively high death rate associated with mild
asthma.37 Given the baseline characteristics in the
current study (i.e. symptomatic on ICS therapy),
there is a strong possibility that a significant
proportion of patients may have been inadequately
treated. Even those with mild disease may have
been suitable for a dose increase or a medication
change.
In the current study, all three treatments were
well tolerated, as shown by the low number of
withdrawals due to adverse events. Combination
therapy represents a rational approach to asthma
management, as it is thought that both ICS and
LABAs can activate glucocorticoid receptors, re-
sulting in the need for lower levels of ICS in
combinations, thus maximising the therapeutic
benefits whilst reducing the side effects of these
agents.38 Kirby et al. demonstrated that in healthy
subjects there is no systemic pharmacodynamic or
pharmacokinetic interaction between inhaled sal-
meterol and FP when given in combination.39
Masking of inflammation has been a concern
associated with LABAs, as the effective bronchodi-
latation caused by salmeterol could mask an
underlying deterioration in the inflammatory status
of the lung.40 However, low-dose combinations may
overcome this concern. The efficacy of the SFC
combination (salmeterol 50 mg; FP 250 mg) in our
study suggests that there was no masking of
inflammation, especially as many patients were
taking ICS at baseline and were still symptomatic.
In conclusion, this present study supports the use
of ICS plus LABAs in a broad population of patients
with mild to moderate asthma. SFC was consis-
tently more effective at long-term asthma control
than FP or salmeterol in a clinically representative
group of patients. The protection against exacer-
bations may be attributed to better control of
inflammation, AHR and lung function parameters
achieved with SFC.Acknowledgments
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